The market's perception of the pharmaceutical company has undeniably shifted.Even a juggernaut like Eli Lilly (LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat, signaling that the market's reception to its financial performance was strongly negative.Shareholders discovered that there's reason to believe that a previously hypothesized risk is now real and that it presents a possible threat to ...

Core Viewpoint - Eli Lilly's stock has experienced a significant decline following its latest earnings report, which failed to meet high analyst expectations, leading to concerns about its valuation and future performance [1][2]. Financial Performance - Eli Lilly's revenue increased by 20% to $11.4 billion for Q3, but this fell short of analyst expectations of $12.1 billion [2]. - Adjusted earnings per share (EPS) were reported at $1.18, significantly below the anticipated $1.47 EPS [2]. Inventory and Supply Issues - The company faced challenges with inventory levels, as wholesalers did not reorder supplies while fulfilling back orders for Mounjaro and Zepbound, potentially leading to shortages in the next quarter [3]. - Strong demand for products exists, but supply chain issues have been a persistent problem for Eli Lilly [7]. Guidance Adjustment - Eli Lilly revised its guidance for the year, projecting adjusted EPS to be between $13.02 and $13.52, down from a previous forecast of $16.10 to $16.60, which disappointed investors [4]. Stock Performance - Prior to the earnings report, Eli Lilly's stock was trading around $900, but it dropped to approximately $800, reflecting a decline of over 10% in just a few days [5]. - The stock was previously trading at more than 100 times its trailing profits, indicating elevated expectations [6]. Long-term Outlook - Despite recent bearish sentiment, there are reasons for optimism, as inventory and supply issues are expected to resolve over time, particularly with increased capacity [7]. - The long-term potential of Mounjaro and Zepbound could lead to significant revenue generation, allowing earnings to align with the stock's high valuation [9]. - Eli Lilly is viewed as a candidate to become the first healthcare stock to reach a $1 trillion valuation, suggesting that buying during periods of weakness could yield good returns for long-term investors [10].

Eli Lilly’s NYSE: LLY market isn’t out of the weeds yet but will rebound strongly in 2025. The Q3 results failed to spark a rally because of underperformance, but the salient details are that growth is robust, driving impressive profits, and is expected to accelerate in 2025. The net result from the release is that analysts are raising their estimates for Q4, next year, and the next five year’s earnings, creating a tailwind for the LLY market.   Eli Lilly and Company TodayLLYEli Lilly and Company$806.14 -12 ...

RIYADH, Saudi Arabia, Nov. 03, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia signed an MoU today to improve Alzheimer’s patient care. The Memorandum would pave the way to transform KFSHRC’s Neuroscience Centre into a regional hub of excellence for Alzheimer’s Disease. The Parties aim to jointly explore initiatives to educate and train Saudi Arabian healthcare professionals about neurodegenerative diseases such as Alzheimer’s, including the l ...

Eli Lilly (NYSE: LLY), one of the U.S.’s foremost pharmaceutical giants, faced a sharp 8% drop in its stock price after reporting disappointing third-quarter results, erasing nearly $70 billion from its market value.The pharmaceutical giant missed both earnings and revenue expectations, prompting several analysts to lower their price targets.LLY five-day stock price chart. Source: FinboldAt the time of writing, LLY stock is down over 8% in the 5-day chart to its press-time price of $818. Sales miss sparks i ...

Size means little in light of this company's prospects.Small-cap stocks have more upside potential since they are riskier assets, so investors demand higher rates of return when investing in them. However, large-cap stocks -- even those at or near a $1 trillion valuation -- can have plenty of room to run, too. That seems to be the case with Eli Lilly (LLY -1.30%), a pharmaceutical giant firing on all cylinders. As of this writing, the drugmaker's market cap is $858 billion, but its prospects look incredibly ...

INDIANAPOLIS, Nov. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader (SERD), will be reported for the first time in a late-breaking oral presentation at the San Antonio Breast Cancer Symposium (SABCS) taking place December 10-13 in San Antonio, TX. EMBER-3 is a study in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast can ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial . We're just days away from the U.S. General Election, which means tensions are running hot. Both sides of the political aisle seem to make the case that if the other side wins, democracy is lost and the economy is in trouble. Analyst's Disclosure: I/we have a beneficial long pos ...

The market overreacted to Lilly's Q3 earnings miss and full-year guidance cut. High-flying aircraft experience turbulence from time to time. It's the same story with stocks. We saw that happen with Eli Lilly (LLY -2.02%) this week. Lilly announced its third-quarter results on Wednesday. Investors didn't like what they heard. The big pharma stock initially plunged close to 15% after the market opened on Thursday before bouncing back somewhat. Even with this partial rebound, Lilly's share price remains roughl ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and onl ...